Santalis’ acne therapy to launch in Asia, USA and Australia under Dr. Ronald L. Moy’s new brand
TFS Corporation Limited (TFS) is pleased to announce that its joint venture entity, Santalis Pharmaceuticals, Inc., has entered into an agreement to supply its over the counter (OTC) acne treatment kit for distribution under Dr. Ronald L. Moy’s new skin care brand. The acne treatment products will initially be available to Australia, Japan, Taiwan, Korea, HK and Hawaii as well as through Dr. Moy’s 4 U.S. clinics in the Los Angeles area, including his flagship office in Beverly Hills, California.
Dr. Moy was the principle investigator on Santalis’ clinical study to evaluate the effectiveness and safety of the acne treatment kit. The results of the 50 patient, open label, phase 2 clinical study were published in the December 2012 issue of the Journal of Drugs in Dermatology (http://jddonline.com). The study demonstrated that the East Indian Sandalwood (Santalum album)-containing acne treatment kit was highly effective in reducing patient inflammatory and non -inflammatory lesion counts, with both minimal side effects and a high compliance and patient satisfaction rate supporting the clinical benefits achieved.
The acne treatment kit is formulated with sustainably-grown, pharmaceutical grade East Indian sandalwood oil (album) supplied by TFS and was designed to provide effective anti-bacterial and anti-inflammatory benefits without the drawbacks often associated with benzoyl peroxide and high dosage salicylic acid products, such as dryness and irritation of the skin.
Dr. Moy, speaking at the recent meeting of the American Academy of Dermatology, said, “I am enthusiastic to be able to provide my patients with a new, clinically proven approach for the treatment of their acne that is provides a safe and effective alternative to the other OTC and Rx options available. I am highly encouraged that they will be able to see significant improvements in the clarity of their skin and will be able to maintain their therapy without experiencing the harsh side effects that often cause them to stop treatment with other products.”
Santalis CEO, Dr. Paul Castella, stated that, “We are delighted that Dr. Moy is launching the acne treatment line based on our proprietary album formulation, having seen firsthand the clinical results that can be achieved with this product. Dr. Moy’s decision represents an important validation of our focus on album’s unique attributes for dermatology applications.”
“The agreement between Santalis and Dr Moy is another very positive step in the development of the global multibillion dollar pharmaceutical and skin care market for TFS produced album oil” TFS Executive Chairman Mr Frank Wilson said.
Dr. Moy is one of the world’s leading cosmetic and plastic surgeons with more than 200 articles on cosmetic and dermatologic surgery and treatments and is a renowned international lecturer on advancing cosmetic surgery technologies. Dr. Moy is board certified in dermatology, and has served as a Professor at the David Geffen School of Medicine at UCLA, the President of the American Academy of Dermatology (2011-2012), the American Society for Dermatologic Surgery (2004-2005), the Pacific Dermatology Association, Medical Board of California (Division of Medical Quality) and Editor-in-Chief of Dermatologic Surgery.
Gerry Bullon email@example.com Ph: 0418 106 675
TFS Corporation Ltd (ASX: TFC) is an owner and manager of Indian sandalwood plantations in northern Australia. As part of its vision to be a vertically integrated producer of finished sandalwood products, TFS owns a significant proportion of the plantations in its own right and in 2008 acquired Mount Romance Australia (Mount Romance), the Albany-based sandalwood processor and oil distributor.
TFS was founded in 1997 to exploit the success of government trials into the plantation growth of Indian sandalwood in the Ord River Irrigation Area (ORIA) of north-east Western Australia.
TFS’s first planting was in 1999 and it now manages the largest area of Indian sandalwood plantations in the world, with approximately 6,500 hectares planted. TFS plantations are managed on behalf of both retail and institutional investors.
TFS will be commencing the first commercial harvest of its Indian sandalwood plantations in 2013.
The company listed on the Australian Stock Exchange in December 2004.
TFS is committed to adopting and maintaining the highest environmental and ethical standards in all aspects of its business. All plantations are grown on land that has previously been used for agricultural or horticultural production. As the first ORIA land owner to recycle its water, TFS was the winner of the 2006 State Regional Water Award. In 2011 TFS subsidiary Mount Romance was awarded the Platinum Award by the Water Corporation for its Water Efficiency Management Plan (WEMP).
TFS is ranked as an industry leader in ethical and sustainable practices by Oekom Research, a leading international ratings agency.
In 2009, TFS entered the prestigious Forbes Asia Pacific's ‘Best Under a Billion’, which recognises the Top 200 companies from more than 25,326 publicly-listed firms in the Asia/Pacific region with revenue of less than US$1 billion.
ABOUT INDIAN SANDALWOOD
Indian sandalwood has a history as a tradeable commodity spanning thousands of years, but is now endangered due to the il egal harvest of wild trees throughout the world. As a result, Indian sandalwood is the world’s most expensive tropical hardwood and continues to increase in price each year. The price of its heartwood has risen at a compounded rate of over 16.7% per annum since 1990.
Indian sandalwood oil is a globally important ingredient in fine fragrances, cosmetics and toiletries, Indian consumer products and for medicinal purposes (Ayurvedic and Chinese medicine) and the wood is used for high quality carvings and artefacts and religious worship in the Hindu and Buddhist faiths.
Indian sandalwood has a well entrenched market throughout the world, particularly in India and China, two of the fastest growing economies in the world.
ERRATUM mediscript StaR - Stand 24.07.2013 Seite 2- Seite Bänder Skript STATUS aktueller Text berichtigter Text Herausgeber und Autoren Band 1 Anita Störmann, München - Kap. 17 sowie Chirurgie-Info-Kästen [AS] Dr. med. Anita Störmann, München - Kap. 17. 2 sowie Chirurgie-Info- Kardiologie/Skript 1 • ausgeglichener Versorgungstyp (20 %)… • ausgeglichener Versorgun
DALBAVANCIN VS LINEZOLID FOR TREATMENT OF ACUTE BACTERIAL INFECTIONS OF THE SKIN: A COMPARISON OF EARLY AND STANDARD OUTCOME MEASURES IN STUDY VER001-9 Michael W. Dunne,1 George H. Talbot,2 Anita F. Das3 1Durata Therapeutics, Morristown, NJ, USA; 2Talbot Advisors, St. Davids, PA, USA; 3Axistat Inc, San Francisco, CA, USA ABSTRACT Table 3. ABSSSI Measurements at Baseline Table 4.